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OF ALL THE LECTURES I have been asked
to give, I count this one as my greatest
honour. Gordon Hamilton-Fairley was a
personal friend, colleague and mentor for
more than 10 years until he was killed so
tragically by a terrorist bomb in 1975. He
was the father of Medical Oncology in
Britain and played an important part in
encouraging the development of academic
departments ofMedical Oncology not only
in St Bartholomew's Hospital where his
own unit was based, but also at the Royal
Marsden Hospital and other centres in
London. His efforts led to Medical Onco-
logy becoming an established subspecialty
in Medicine andthe development ofseveral
major academic departments in the speci-
alty outside London (e.g. Manchester,
Glasgow, Edinburgh and Southampton).
There is now a sound base for training and
doctors of high calibre with a strong back-
ing in clinical oncology and research are
now available to fill new posts in Medical
Oncology. Such posts are undoubtedly
needed in view of the increasingly import-
ant role of systemic treatment in im-
proving the survival of patients with
cancer. The number of posts must be
tailored to the relative work load and
research requirements in chemotherapy,
radiotherapy and surgery. My own view is
that, initially, such posts should be intro-
duced in close association with existing
Departments of Radiotherapy in our
major cities and, following this, physicians
with a special interest and training in
Medical Oncology could be appointed to
local district general hospitals to improve
chemotherapy services in the region. This
is the pattern of development which is
being encouraged in the north-west of
England.
My talk concerns new approaches being
made in the management of patients with
non-Hodgkin's lymphoma (NHL) of high-
grade pathology (i.e. those composed of
large cells arranged in a diffuse pattern)
and I will colour my presentation with
data from studies being undertaken in
Manchester, in both the clinic and the
laboratory.
A recent publication of the Office of
Population Censuses and Surveys (1980)
is rather disturbing. The 5-year survival
of patients with NHL in England and
Wales has not improved significantly over
a period of almost 10 years, in spite of
notable improvements in chemotherapy
(Table I). The overall 5-year survival of
about 300/o must be considered in the
context of an expected 50%o in the
subgroup with low-grade histology treated
in a palliative manner with low-dose
single-agent chemotherapy and radio-
therapy. This means that patients with
high-grade histology are faring badly, and
the object of the first part of my talk is to
suggest that the new approaches now
being adopted for this unfavourable group
of patients in special centres should lead
to an improvement in survival in the
country as a whole.
* Delivered at the joint meeting of the British Association for Cancer Researcht and(i Section of Oncology, Royal Society of Medicine, December 11th 1980.
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TABLE I.-Cancer statistics survival, Eng-
land and Wales (OPCS, 1980)
Non-Hodgkin's Lymphoma (NHL)
Year Diagnosis
1964-66 RSa/LSa*
Other
1971-73 RSa/LSa
Other
Sex
M
F
M
F
M
F
M
F
No. regis-
tered
2928
2319
556
553
2785
2435
926
777
5-yr sur-
vivals (0%
corrected)
24-3
26-3
41-9
39.9
30-1
31-7
42-8
42-7
* Reticulo-sarcomas and lymphosarcomas.
In NHL patients careful documentation
of the extent of disease is important in
determining the part to be played by local
treatment such as surgery or radiotherapy,
and is necessary in defining the role of
chemotherapy. Although some patients
can be cured by radiotherapy or surgery
alone, not more than 10% of all patients
achieve long-term relapse-free survival
following local treatment alone. Chemo-
therapy, therefore, has a major role in
these diseases.
CHEMOTHERAPY FOR GENERALIZED
DISEASE
Combination chemotherapy used inter-
mittently has proved to be of greater
value than single-agent chemotherapy in
patients with high-grade lymphomas and
complete remissions are now obtained in
40-70% of treated patients. Several retro-
spective studies have been reported re-
cently showing an advantage in using
Adriamycin-containing regimens in terms
of rate of complete remission and relapse-
free survival (Cabanillas et al., 1978;
Jones et al., 1979; Johnson et al., 1979;
MacKintosh et al., 1980). The role of
cyclophosphamide in the induction pro-
gramme is less clear, with at least one
report showing an advantage to an
Adriamycin-containing combination with-
out cyclophosphamide (Bodey & Rod-
riguez, 1978).
The duration of relapse-free survival
after induction of complete remission is
dependent upon the histological subtype,
with those classified as diffuse "histio-
cytic" lymphomas using the Rappaport
classification having long-term relapse-
free survival compared with a continuing
relapse pattern for those classified as
diffuse poorly differentiated lymphocytic
(Schein et al., 1975).
The group at the National Cancer
Institute, Bethesda, reported a complete
remission rate in 56 patients with diffuse
histiocytic lymphoma of 47%. Although
the overall median survival was poor (14
months), one third of the patients sur-
vived in complete remission at 5 years.
Very few patients relapsed if they were
still in remission one year after induction
of remission using combination chemo-
therapy, and the suggestion was made
that these patients could well be cured
(Fisher et al., 1977).
Most reports have involved combination
chemotherapy given intermittently, but
the poor median survival illustrates the
propensity for early relapse and death in
more than half the patients. The recog-
nition that treatment failure frequently
occurs early in the first few months of
induction chemotherapy, with failure to
achieve complete remission and a tendency
to relapse between courses, led to the
introduction of a more continuous form of
chemotherapy using combined chemo-
therapy involving a weekly schedule at
St Bartholomew's Hospital in 1972. The
combination was similar to that successful
in treating acute lymphoblastic leukaemia,
and involved vincristine, prednisolone,
Adriamycin and L-asparaginase (OPAL).
We recently reported the results of treat-
ing a small number ofpatients with diffuse
histiocytic lymphoma using this approach
(Lister et al., 1978). All 10 patients with
Stage III disease and 6/11 patients with
Stage IV disease achieved a complete
remission, and preliminary results showed
promising long-term relapse-free survival.
The Manchester Lymphoma Group has
addressed the problem of early failure
using a similar approach (Blackledge et al.,
1980b). More than 18 months of further
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follow-up is now available for patients in
this study, and updated results are in-
cluded here. Induction chemotherapy con-
sisted of prednisolone (40 mg orally daily
for 6 weeks), vincristine (2 mg weekly i.v.
for 6 weeks) and 3 i.v. injections of
Adriamycin (50 mg/M2) at 2-weekly
intervals (VAP). In addition, local radio-
therapy was given to areas of residual or
previously bulky disease in an attempt to
reduce the relapse rate in these areas.
Subsequent chemotherapy involved a 2-
year programme of continuing therapy
using cyclophosphamide (200 mg/M2),
methotrexate (10 mg/Mi2 orally weekly)
and 6-mercaptopurine (50 mg/M2 orally
daily). The doses were tailored to maintain
the white blood count 3000-3500/pl.
One hundred and seven patients entered
the study between 1975 and 1980. There
were 19 patients with Stage II abdominal
involvement and massive nodal disease;
11 of these had gastrointestinal involve-
ment. Eighteen patients had Stage III
disease and 70 Stage IV disease. The age
range was 19-70 years and the overall
complete remission rate was 62%. Twenty
five patients achieved a good partial re-
mission, with only minimal residual
disease remaining. Six further patients
had a remission with a tumour regression
of >50%, and only 10 patients were
classified as failures (<50% regression).
A multivariate analysis offactors affecting
TABLE IT.-Multivariate analysis of vari-
ables influencing the probability of com-
plete remission in 107 patients with
lymphomas ofdiffusepathology (NHD4/1
Study, Manchester Lymphoma Group,
October 1980)
Variable
None
Alkaline
phosphatase
+Age groups
+B symptoms
+Marrow
+ Sex
Scaled De-
deviance crease
134-6
120-7
115-0
109-1
101-8
97-7
13-9
5-7
5-9
7-3
4-1
Favour-
able
P feature
0-0002
0-017
0-015
0-007
0043
Normal
Young
Absent
Normal
Female
A step-up procedure was used for the analysis.
probability of achieving a complete re-
mission revealed 5 factors of independent
significance (Table II). Increased serum
alkaline phosphatase, increasing age, pres-
ence of B symptoms, marrow involve-
meiit and male sex were all associated
with a significant reduction in the prob-
ability of a complete remission. There was
no difference in complete-remission rate
between patients with diffuse histiocytic
and diffuse poorly-differentiated lympho-
cytic lymphoma. The median duration of
follow-up was 4 years, and the overall
survival in the 107 patients is shown in
Fig. 1. Survival was related to a number
of pretreatment variables: the influence
of stage B symptoms, gastrointestinal
tract involvement, overall assessment of
liver function, alkaline phosphatase,
serum albumin, histology, peripheral-
blood lymphocyte count and haemoglobin
were all assessed individually in relation
to survival, and following this a Cox re-
gression analysis was performed. Four
100-
80
60-
0
.C ',
0 1 2 3 4 5
Years
FiG. 1. Overall survival of 107 patients
with diffuse histiocvtic, diffuse poorlv
differentiated lymphocytic, diffuse mixed
and diffuse undifferentiated lymphomas,
trcated with the VAP protocol.
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TABLE III.-Cox regression analysis of variables influencing survival in 107 patients with
lymphoma ofdiffuse pathology
Log
Variable likelilhood Increase T) Unfavoourable feature
Albumin 8-45 8-45 0 00004 Low albumin
+Stage 12 60 4-15 0 004 Stage IV
+Alkaline phosphatase 15-21 2-61 0-023 Raised
+Pathology 17-14 1-93 0.05 Histology otliertlha
diffuse histiocvtic
Eachi of the 4 variables hias a significant effect on survival after a(djustment for the other 3.
(I 'I OId B I~ O a:alllo
en~~~~~~~~~~~wg uLn-t
0
Cl)
40-
Stag IV n=70
20-
0 1 2 3 4 5
Years
FIG. 2. Survival related to stage (P = 0 003).
Stage II patients were a group with
abdominal or gastrointestinal involvement,
but no evidence of spread outside the
abdomen.
variables, including a low serum albumin,
Stage IV disease, high serum alkaline
phosphatase and diffuse histiocytic path-
ology, had a significant effect on survival
after adjustment for the other 3. None of
the other pretreatment variables had a
statistically significant effect on survival
after adjusting for the effects of these 4
variables (Table III). Patients with ab-
dominal Stage II disease did particularly
well under this treatment policy, with
more than 70% surviving, relapse-free,
beyond 4 years (Fig. 2). Survival was also
closely related to remission status which
was of individual prognostic significance,
Cl,
0
Cl)
0
CR n=66
PR n=6
I] F n=10
0 1 2 3 4 5
Years
FIG. 3.-Survival related to remission status
(P < 0-00001). Complete remission (CR) was
defined as resolution of all evidence of
lymphoma. Good partial remission (GPR)
included patients with > 90% reduction in
tumour masses. Partial remission (PR) was
defined as > 50% but < 90% reductioni in
the mass of disease and failure (F) was
< 50% reduction in the mass of disease.
with 60% of those achieving a complete
remission surviving for more than 4 years.
Failure to achieve a complete remission
was associated with a poor survival
(Fig. 3).
There was a statistically significant
difference in survival (P=0 001) and
relapse-free survival (P= 0.01) in patients
who received bulk radiotherapy after
induction chemotherapy. The improved
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surxvival seen in patients receiving radio-
therapy was still significant after adjust-
ment for the effects of the 4 pretreatment
variables in Table III, but this treatment
was not randomized, and the data must
be interpreted with caution. The results
suggest that a prospective randomized
study of radiotherapy following induction
chemotherapy could be well worthwhile.
Skarin and his colleagues from Boston
(Skarin et al., 1980) have recently reported
data on another frequent chemotherapy
schedule which lends support to the sug-
gestion that this approach may lead to
improved complete remission rates and
long-term relapse-free survival. A group
from Seattle (Sullivan et al., 1979) have
also suggested that radiotherapy could
have a useful role following initial chemo-
therapy and one third of the patients
completed their remission using radio-
therapy in their series. The radiotherapy
given included whole-body irradiation if
the marrow was involved, and this
approach, which was more aggressive than
our own, may have contributed to the
higher complete-remission rate. The con-
tribution of these different forms of radio-
therapy to the improved survival in
patients with diffuse lymphomas deserves
further study under controlled conditions.
The appreciation that patients with
some forms of diffuse pathology have a
continuous relapsing pattern and poor
survival in spite of a high apparent initial
remission rate is disappointing. A more
intensive approach using combined
chemotherapy and radiotherapy may lead
to further improvement in survival, but
this remains to be tested. In my view, a
radical approach following the induction
of remission is now required. In contrast
with diffuse histiocytic lymphoma, where
high-dose irradiation frequently fails to
control local disease, recurrences in the
irradiated area after moderate-dose radio-
therapy for diffuse lymphocvticorlympho-
blastic disease are less common (Fuks &
Kaplan, 1]975). Low-dose whole-body
irradiation (1-3 Gy) has proved of some
valuie in the control of lymphocytic
lymphomas, though it is no better than
chemotherapy, and myelodepression con-
tributes to difficulties in later treatment
(Johnson et al., 1978). For these reasons,
an approach using combined intensive
combination chemotherapy with higher-
dose whole-body irradiation (1I Gy) for
selected patients with diffuse poorly
differentiated lymphocytic or lympho-
blastic forms of lymphoma is now worth
studying. The marrow is frequently in-
volved in such patients, and homologous
marrow transplantation would be re-
quired. The promising results in patients
with acute leukaemia using this approach
provide a good argument for studying this
new method of treatment in patients with
diffuse lymphoma in whom a, complete
remission has been achieved.
Central nervous system (CONS) involvement
Involvement ofthe CNS is a well known
complication in patients with lymphoma.
The reported incidence varies from < 5o
to > 25%, with the highest incidence in
patients with diffuse histology. However,
few patients are likely to benefit from
prophylactic treatment of the CNS, since
most patients in whom CNS involvement
develops present at a time of advancing or
uncontrolled disease in other areas (Young
et al., 1979). In addition, the routine
prophylaxis may compromise the ability
to deliver adequate chemotherapy for cure.
For these reasons, the careful selection of
patients at high risk is mandatory if
prophylaxis is to be tested. Further study
of this topic is also warranted because the
choice of effective therapy for CNS disease
is in doubt. Our policy in the Manchester
Lymphoma Group is to avoid prophylactic
treatment of the CNS until further data
accrue on the incidence of CNS relapse in
patients who are otherwise in complete
remission.
CHEMOTHERAPY FOR LOCALIZED DISEASE
Localized or regional radiotherapy may
produce prolonged relapse-free survival in
about half the patients with lymphomas
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of diffuse pathology presenting with
clinically localized disease (CS I/II).
Patients with diffuse histology constitute
about 80% of the total presenting with
local disease. A recent analysis of data
from St Bartholomew's Hospital showed a
50% relapse-free survival for 29 patients
with diffuse poorly-differentiated lympho-
cytic, compared with 34% of 32 patients
with diffuse histiocytic histology (Timothy
et al., 1979). Their results are similar to
other recently published series from
Canada (Bush et al., 1979) and the United
States (Chen et al., 1979), and are con-
sistent with the earlier literature (see
review, Bonadonna et al., 1976). The re-
lapse rates for patients with CS II disease
are higher than for CS I disease. Analysis
of local failures shows that nearly all in-
volved diffuse tumours and, in contrast
with nodular tumours, these can prove
difficult to control, even with high-dose
irradiation (Fuks & Kaplan, 1975). Nearly
all relapses, however, occur by wide dis-
semination, and chemotherapy therefore
has an important role in this context in
preventing the growth of tumour in these
disseminated sites and the recurrence of
tumour in areas treated previously with
radiotherapy.
The Milan group have reported their
5-year follow-up data of a controlled ran-
domized trial of combination chemo-
therapy used as an adjuvant after radio-
therapy for pathological stage (PS) I/II
NHL (Monfardini et al., 1979). After treat-
ment with regional radiotherapy, patients
in complete remission were randomized to
receive either no further therapy or 6
cycles of CVP (cyclophosphamide, vin-
cristine and prednisolone). A total of 96
patients were evaluable. At 5 years from
completion of irradiation, the relapse-free
survival was 46% after radiotherapy and
72% after radiotherapy with CVP (P=
0.005). The corresponding findings for the
overall survival calculated from the begin-
ning of irradiation were 55% and 83%
respectively (P= 0.03). The favourable
effect of adjuvant chemotherapy on re-
lapse-free survival was statistically signifi-
cant, irrespective of stage and clinical
presentation in the subgroup with diffuse
histology which represented more than
70% of the entire series. In contradistinc-
tion, patients with nodular histology
showed no improved relapse-free survival
after 6 cycles ofCVP. In patients relapsing
after radiotherapy alone, salvage therapy
failed to induce a high incidence of second
durable remissions. Thisstudyisimportant
in that 98% of the patients had patho-
logical staging (26% by laparoscopy and
74% by laparotomy). Glatstein and his
colleagues from Stanford (Glatstein et al.,
1977) reported a study in which they failed
to observe an improvement in overall sur-
vival or relapse-free survival in PS 1/11
patients with high-grade histology using
total nodal irradiation with CAT (cytosine
arabinoside, Adriamycin and thioguanine)
for diffuse histiocytic lymphoma, and
CVP for all other histologies. This was also
true for the study reported by Panahon
et al. (1977). The reason for these different
results may well be related to the differ-
ences in the radiotherapy rather than the
chemotherapy used in the studies.
A study from Stockholm supports the
findings of the Milan group (Landberg et
al., 1979). Fifty five patients with nodular
or diffuse lymphoma of CS I/II were
randomized for 9 cycles of CVP after
radiotherapy; the relapse-free survival at
30 months was 41% for patients without
and 86% for patients with adjuvant
chemotherapy (P=0 02). Survival was
the same for both treatment arms, being
90% at 30 months. Analysis of the sub-
groups showed that adjuvant chemo-
therapy significantly prolonged the re-
lapse-free survival in diffuse histiocytic
lymphoma, but there were only 20
evaluable patients in this group. This
study suffers from the defect of small
numbers of patients and short follow-up.
The Manchester Lymphoma Group is
conducting a study comparing the effects
of two forms of combination chemo-
therapy as an adjuvant after radiotherapy
for nodal stages I/II disease. Patients with
Stage IE disease were not included since
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these have a relatively good relapse-free
survival after radiotherapy alone. The
chemotherapy was either 6 courses of a
combination withoutAdriamycin (CMOPP
-cyclophosphamide, vincristine, procarb-
azine and prednisolone) or the regimen
used by the group for advanced stages of
high-grade lymphoma (vincristine, Adria-
mycin and prednisolone for 6 weeks fol-
lowed by 2 years oral 6-mercaptopurine,
cyclophosphamide and Methotrexate).
Only 5/34 patients have relapsed (median
follow-up 21 years) with a 3-year relapse-
free survival of 88%. As yet, there is no
significant difference between the treat-
ment arms, since the number of events is
too low.
The recognition that chemotherapy
alone can produce long-term relapse-free
survival in patients with Stage III/IV
diffuse histiocytic lymphoma, and that
adjuvant chemotherapy prolongs survival
and relapse-free survival in carefully
staged localized diffuse histiocytic lymph-
oma has prompted the use of chemo-
therapy alone in patients with Stage I/II
lymphoma of this type. Miller & Jones
(1979) retrospectively analysed a series of
22 patients with diffuse lymphoma, Stages
I/II, treated with chemotherapy alone (14
patients) or chemotherapy with local
irradiation. All 22 patients achieved a
complete remission and remained alive
(median survival 27 + months). Twenty
one patients remained continuously free
of disease, with a median relapse-free
survival from completion ofchemotherapy
of 23+ months. Most patients received
CHOP chemotherapy (cyclophosphamide,
Adriamycin, vincristine and prednisolone).
It seems that chemotherapy now has an
established role in the treatment of Stage
1/11 lymphomas of high-grade histology.
STAGING
The studies I have already mentioned
emphasize the importance of staging. A
further example of the important role of
careful staging can be obtained from a
study of patients presenting with gastro-
intestinal lymphoma. A recent retro-
spective series of patients with gastro-
intestinal lymphoma presenting at the
Christie Hospital, Manchester, has been
analysed by our group (Blackledge et al.,
1979). There were 104 patients with full
details of the surgery obtained. Although
the median survival was only 15 months,
35% were alive and well at 10 years. The
tumour type (histology, site and whether
single or multiple) extent of lymph-node
involvement and the presence of local
extension to adjacent organs, perforation
with peritonitis or distant metastases were
of considerable prognostic importance.
The Ann Arbor staging classification was
inadequate for this group of patients, and
a new staging system for gastrointestinal
lymphoma has been proposed, which has
prognostic significance and can be used to
select appropriate poor prognostic groups
for chemotherapy. It was clear from the
data that patients fared much better if
tumour excision was complete. Each of
the patients had initial surgery involving
laparotomy, and all apparent tumour was
removed in 41 patients. This included
removal of locally involved nodal masses
and tumour which had spread to adjacent
tissues. The group had a much better sur-
vival than the remainder with either in-
complete tumour removal or merely
tumour biopsies (P=0.0005). Of the 49
patients who had complete removal of the
tumour, only 11 had a single tumour con-
fined to the gut; all the others had either
local nodes involved or spread to adjacent
tissues. Considering only Stage II patients
with disease extending outside the gastro-
intestinal tract, there was still a highly
significant difference between the patients
with complete and incomplete removal of
the tumour (P=0.004). Cure is a distinct
possibility after surgery alone for patients
with gastrointestinal lymphoma, but
tumour removal must be complete. Other
groups with incomplete removal have a
poor survival, in spite of the addition of
radiotherapy, and early chemotherapy is
then of recognizable value.
Unlike most forms of nodal lymphoma,
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gastrointestinal lymphoma has a propen-
sity for remaining apparently localized to
the gut wall and draining lymph nodes
(gastric or mesenteric) allowing a moder-
ate proportion of cures by surgery alone.
Peripheral nodes become palpable late in
the history of the disease, if at all, and in
this series, only two patients had a palp-
able spleen at presentation. Only 20% had
widespread nodal disease; involvement of
adjacent organs after spread through the
bowels was more common than indirect
metastatic spread to distant organs, and
the bulk ofdisease remains confined to the
abdomen for most of its course. For these
reasons, the Ann Arbor classification,
which is so useful for nodal Hodgkin's
disease, is less appropriate for gastro-
intestinal NHL. A study of the pattern of
lymphoid-cell migration can offer an
explanation of the difference between
gastro-intestinal lymphoma and other
forms of lymphoma, and will be discussed
later.
Wt'hole-body scanning with computed
tomography (CT)
Surgical staging is not recommended for
most patients presenting with NHL,
since laparotomy is potentially dan-
gerous and generalized disease can usually
be documented by conventional clinical
staging. Treatment decisions are usually
based on staging procedures which avoid
laparotomy in this group of patients. CT
has enabled a more accurate documenta-
tion of the pattern of disease at presenta-
tion than could be achieved by conven-
tional clinical staging alone, and therefore
plays an important part in initial staging.
Its advantages over abdominal lympho-
graphy have previously been documented
(Crowther et al., 1979). In Manchester,
whole-body CT has replaced abdominal
lymphography in lymphoma patients.
At presentation and clinical relapse, CT
scanning detects unsuspected disease in a
high proportion of patients with lymph-
oma, and has an important influence on
treatment policy. The evaluation of re-
sponse to chemotherapy and the detection
TABLE IN'.-Abdominal C(T scan results in
patients with diffuse-pathology lymphoma
in apparent clinical remission by con-
ventional restaging methods (excluding
lymiphography)
No.
CT normal 22
CT abnormal 21
AlivNe
relapse-
free
21
5
Eelapsed
or
lead
16
P= 0 0000 1.
of bulk disease for subsequent radio-
therapy are of additional importance in
patient management, and the technique is
of great value in documenting remission.
Preliminary data on the importance of
assessing remission status after treatment
and the value of CT in this context has
previously been published (Best et al.,
1978). An update of these results in
lymphomas with histology of diffuse
large-cell type is shown in Table IV.
Forty-three patients had abdominal CT
scans when they were considered to be in
complete clinical remission after chemo-
therapy. Conventional restaging methods
were used with documentation of re-
mission, using biochemical, haemato-
logical (including marrow aspiration and
trephine assessment), cerebro-spinal fluid
examination and conventional radiology
(excluding lymphography and CT scan-
ning). All patients showed resolution of
symptoms and signs of pre-existing
lymphoma. Of the 43 patients, 21 had
abnormal CT scans, and 16 of these have
relapsed or died of lymphoma. Of the 5
with abnormal scans who are alive and
well, 2 who showed persistant disease
within 2 months of clinical remission had
a regression with further treatment over
the ensuing months. Of the 22 patients
with normal scans, only I has relapsed.
This study emphasizes the importance of
carefully documenting remission status in
these patients, and its reflection on sur-
vival has been shown in Manchester
Lymphoma Group data (Fig. 3).
In passing, it must be said that results
in patients with nodular lymphoma were
different, and showed no difference in
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ilelapse-free survival or overall survival
between those with abnormal scans and
patients with no evidence of disease on
CT scans (unptublished data).
An accurate documentation- of sites of
relapse is important in deciding the most
appropriate therapy for patients with
evidence of recurrence. CT has proved to
be extremely helpful in this respect. Of 27
patients relapsing with diffuse histology,
23 had abnormal CT scans, and CT de-
tected about twice as many areas of in-
volvement as was expected by conven-
tional clinical restaging. Table V' shows
rIABLE V. Abdomtinal sites involved in
patients with relapsing lymphoma detected
by CT (50 patients)
I'atient iiumnber
Abdominal CT scan
abnormal
.Areas involved
1Retr o-erural nodle
P'ara-aortic no(le
Iliac nodes
Coeliac no(les
M\lesenteric no(les
Liver
SpleeIn
Splenic lilar niode
Otlher areas
Total
Nodular
hiistology
23
18
C'linically
Ex- Unex-
pected pectecl
0 7
1'3 7
9 3
() 5
1 5
6 :3
5 4
o) I
4 :3
38 38
I)iffuse
histology
27
Clinically
Ex- Unex-
pected pected
3 5
6 7
7 1
4
0 4
5 1
4 3
() 1
7 0
32 26
details of sites iiivolved in patients with
nodular and difftse pathologies. Lympho-
graphy was not performed routinely in
this grouip as a relapse investigation, but
it is likely that, of the 50 unexpected
lymph-node areas that were shown to be
involved by CT, lymphography would
have detected only 11 (23o%) of them,
these being in the iliac and mid or lower
para-aortic regions. All but 3 of the 15
retrocrural abnormalities were unsus-
pected clinically, and coeliac or mesenteric
nodes were rarely suspected by conven-
tional restaging, though they were seen to
be enlarged in 1 9 cases using CT.
HUMAN LYMPHOCYTE TRAFFIC
I would now like to turn to a topic that
L has interested my group for the last few
years; namely lymphoid cell traffic in man
and its relationship to the behaviour of
malignant lymphoid cells in vivo. The
I studies in man were largely performed by
Dr John Wagstaff in my department, but
important contributions to their success
have been made by Mr C. Gribson, Dr N.
Thatcher and Professor W. Ford (Depart-
ment of Experimental Pathology, Man-
chester University).
The migratory pattern of different
normal lymphocyte populations is known
to be of fundamental importance in the
development of an immune response.
Although the migration of lymphocytes
from blood to the tissues and their return
has been well established in small experi-
mental animals, using autoradiographic
techniques and cannulation oflymphatics,
data in humans are sparse. A study of the
migration of clones of malignant lymphoid
cells in both animals and man could well
lead to a better understanding of the
physiology of normal lymphocyte migra-
tion and help to explain the pattern of
distribution in malignancies. Such studies
are analagous to the studies of inherited
cellular immune deficiencies which help to
dissect the mechanism of the immune
response in man.
It has been observed in rats with Roser
leukaemia that coeliac nodes enlarge by a
factor averaging over 500 whereas super-
ficial cervicallymphnodesundergo onlya 4-
fold enlargement. Further study has shown
that preferential migration of lymphoma
cells from the blood to the coeliac node in
this condition contributed to the unusual
pattern of distribution (Ford, 1978).
Lymphoid blast cells arising from stimu-
lation with an allogeneic graft, however,
also show a predilection for the coeliac
node, but in this situation the node does
not become excessively large, since the
cells have a short transit time (Smith et
al., 1980). Preferential migration and
alterations in transit time may therefore
be of major importance in determining a
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pattern of disease distribution. Ford has
suggested that the high incidence of
coeliac-node involvement in Hodgkin's
disease could be explained by migration
of tumour cells via the blood to the liver
and thence to the coeliac node, rather than
by retrograde lymphatic spread. In addi-
tion, the use of lymphoma lines in experi-
mental systems has indicated that there
may be differences in the high endothelial
venules of different tissues and organs
through which lymphocytes migrate
(Butcher & Weissman, 1980).
Surface-marker and enzyme studies
have shown that the malignant cell in
most NHL patients is of lymphocyte
lineage. A study of the migratory be-
haviour of these cells is therefore likely to
be ofimportance, not only in understand-
ing more about the nature of the immune
deficiency in these patients, but also may
help explain the pattern of spread in the
various types of malignant lymphoma.
For example, an understanding of the
migratory behaviour of lymphoid cells
offers an explanation of the disease dis-
tribution pattern seen in the gastro-
intestinal lymphomas, where the main
bulk ofdisease remains confined to the gut
and mesenteric node areas for a consider-
able period in an appreciable proportion
of patients. It is now recognized that
lymphocytes from gut-associated lymph-
oid tissue have characteristic recirculation
patterns (see review by Hall, 1980).
Immunoblasts and small lymphocytes
obtained from efferent lymph draining the
small intestine, preferentially home to
regions adjacent to the lamina propria or
to the small intestine (very few to periph-
eral nodes or to the large intestine).
Immunoblasts and small lymphocytes
obtained from efferent lymph draining
peripheral nodes, on the other hand,
preferentially home to peripheral nodes
and spleen. Both T and B cells have sub-
populations with migratory characteris-
tics of peripheral nodal or intestinal type.
It is to be expected that if the phenotype
responsible for this migration pattern is
conserved in patients with lymphomas
arising fromgut-associated lymphoid cells,
the bulk of tumour would be confined to
those areas for a prolonged period in spite
ofblood involvement.
Many of the techniques used for the
study of lymphocyte migration in experi-
mental animals are invasive and impos-
sible to carry out in man. The few human
studies have mainly used Na251CrO4
labelled lymphocytes; a technique with
many disadvantages. McAfee & Thakur
(1976) showed that Indium-ill oxine
conjugate was an efficient means of
labelling cells in vitro, and studies using
Indium-ill oxine as a lymphocyte label
have demonstrated that more reliable
information on lymphocyte kinetics in
animals systems can be obtained by this
method (Rannie et al., 1977a,b; Chisholm
et at., 1978; Issekutz et at., 1980; Sparshott
et al., in preparation). Lavender et al.
(1977) showed that external imaging of
11lIn-labelled lymphocytes was possible
in man, and following studies in Man-
chester, the method has an established
value in following the traffic of normal
lymphocytes and their malignant counter-
parts in man (Wagstaff et at., 1981a,b).
Indium-ill oxine is a lipid-soluble
complex with a high labelling efficiency,
a low elution rate, and produces Auger
electrons which allow autoradiography.
The gamma emission spectrum is ideal for
externalimaging on a conventional gamma
camera. By using a combination of
gamma-camera imaging and surface-probe
counting, it is possible to assess the
changing patterns of distribution of
lymphocytes in man followingre-injection.
When the lymphocyte population from
control subjects (predominantly T cells) is
labelled and re-injected, the number of
labelled cells in the blood falls during the
first 4 h. The cells leaving the blood mainly
accumulate in the spleen, which shows
increased imaging during this initial
period. There is an increase in labelled
cells in the blood during the 4-24 h period
during which the splenic activity falls by
about 40%. During this period the cells
accumulate in lymph nodes. The transit
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FIG. 4. Blood-clearance curves, together with spleen and liver uptake, of indium-111 oxine-lahelled
lymphocytes from a normal subject. The secondary rise oflabelled lymphocytes in the blood (at 4 h)
is seen at a time when the surface probe counts over the spleen are decreasing.
time of small lymphocytes through the
human spleen seems to be similar to that
in small experimental animals, and pre-
liminary data suggest that the traffic into
and out oflymph nodes also approximates
to that found in experimental animal
systems. The data are consistent with the
T cells leaving the blood and entering the
spleen after re-injection. After 4-6 h, they
would have traversed the splenic white
pulp and reappeared in the blood, causing
the observed secondary rise in the blood-
clearance curves (Fig. 4).
The transit of different lymphocyte
subpopulations in the blood make an
important contribution to the magnitude
of the immune response in vivo, and
quantitative aspects of lymphocyte traffic
are important in the interpretation of in
vitro immunological studies of lymphoid
cells taken from the blood. Much less time
is spent in the blood than in the other
tissues where immunoclogical reactions
take place, and the relative numbers of
lymphocytes measured in the blood with
different functional characteristics may
not reflect the magnitude of the immune
response.
Patients with a monoclonal expansion
of the B-cell subtype in the peripheral
blood show a different distribution pattern
of re-injected lymphocytes from normal
controls, or from lymphoma patients with
no apparent monoclonal B-cell expansion
in the blood. Seven patients with chronic
lymphocytic leukaemia (CLL) have been
studied and all showed a rapid exponential
decrease in the percentage of labelled
lymphocytes in the blood volume (Fig. 5)
(Wagstaff et al., unpublished). Unlike con-
trols, CLLpatients showedno evidence ofa
riseoflabelledcellsinthebloodinthe4-24h
period. Patients with CLL or lymphomas
with B lymphocytosis showed a con-
tinuous rise in uptake by the spleen
between 4 and 24 h, with a fall between
24 and 48 h. This contrasts with the fall in
counts over the spleen 4 h after the re-
injection ofnormal lymphocytes into con-
trol subjects. The more continuous re-
moval oflabelled B cells from the blood in
the patients with B-cell malignancy sug-
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Fie(1. 5.-Blood-clearance cur.-es, together with spleen and liver uptake of indium- oxine-labelled
lymphocytes from a patient with chronic lymphocytic leukaemia. Unlike normal lymplhocytes
(Fig. 4) there is no secondary increase of labelled cell sin the blood following their rapid clearance,
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gests that even at 48 h, few labelled cells
have returned to the blood after primary
localization. The distribution to heavily
involved organs such as the liver and
marrow in these patients has also been
observed. Marrow imaging is more intense
in CLL patients than in control subjects.
It does not follow that the kinetics of
migration of these cells is related to their
malignancy, however, since it is known
that B cells in animals have a more pro-
longed migration pattern than T cells
(Ford, 1975 review). T lymphocytes
generally recirculate much more rapidly
than B cells, though they leave the blood
by crossing the post-capillary venules in
lymph nodes at the same rate. T cells have
a mean transit time of 5-6 h through the
spleen, and 16-18 h through lymph nodes,
compared with B cells which have not left
the spleen in significant numbers by 24 h
after re-injection and have a mean transit
time of 30-36 h through the lymph nodes.
The observed difference in distribution
seen in patients with lymphoid-cell malig-
lignancy could be explained by the pro-
portion of T and B cells used, since T cells
migrate more rapidly through the spleen,
the major site of primary localization of
lymphocytes. The subsequent rise and
plateau seen under normal circumstances
could be due to the reappearance of
labelled T cells in the blood that have
passed through the spleen. The question
of whether CLL B lymphocytes have
migratory properties similar to normal B
cells needs to be answered. This should
be possible with further work using the
llln-oxine labelled lymphocytes.
Other subsets of lymphocytes within
the blood are known to have different
patterns of migration in experimental
systems, and gut, lung and salivary
lymphoid tissue may well have character-
istic migratory patterns. Further work on
this important new concept, using experi-
mental animals, would be well worth-
while.
Using l1lln oxine-labelled cells, it can
be shown that some patients with other
malignancies have an extremely large flux
of lymphocytes through tumour tissue.
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Fig. 6, for example, shows a scan of the
chest in a patient with nodular sclerosing
Hodgkin's disease involving the medias-
tinum a few hours after injecting his own
labelled lymphocytes. A very large num-
ber of labelled lvmphoid cells has been
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FIe. 6. (a) A plain clhest X-ray slhoN
medliastinal enlargement with nod:
sclerosing Hodgkin's (lisease. (b) Garr
camera picture 24 h aft!er the patient's
peripheral-blood lymplhoctyes labelled
inidiim- 111 oxine were re-injecterl.
taken up by the mediastinal tumour, and
visualization of the enlarged nodes may
occur as early as 30 min after re-injection.
Such a flux of lymphocytes may be an
important mechanism enabling contact
to be made between tumour tissue and the
reactive lymphoid cells which are known
to be in the blood of patients with
Hodgkin's disease (Crowther et al.,
1969a,b). These cells are similar to those
seen in the blood after antigenic stimu-
lation.
Although an antigenic stimulus pro-
motes lymphocyte migration, antigen
specificity does not appear to contribute
to the initial homing. Lymphocyte migra-
tion is, however, facilitated by an increase
in local blood flow, and this appears to be
an important mechanism for bringing
antigen-specific lymphoid cells into appro-
priate contact with foreign material at
sites of inflammation (Hay et al., 1980).
We are also hoping that the technique
will shed light on the cause ofthe lympho-
paenia in patients with malignant disease
and its relationship with prognosis.
CLASSIFICATION
s 5 Classification of NHL by conventional
histopathological techniques is notoriously
tinreliable, and the large number of histo-
pathological classifications available re-
flects this problem. The cell types can be
described, but the cell lineage and differ-
entiation cannot be determined without
more sophisticated techniques.
Normal lymphoid cells and their malig-
nant counterparts have been reported to
vary in their biochemical properties, and
variation in surface glycoproteins, mem-
brane-transport molecules, content of
metabolites such as glycogen, ability to
n. go synthesize certain amino acids and specific
enzyme content has been observed. Bio-
chemical characterization is proving of
wing objective value in classifying lympho-
lular proliferative tumours in addition to
ima- routine histological techniques. Hetero-
own geneity oflymphoidmalignancies has been
demonstrated within the T-cell, B-cell and
lhk
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non-T, non-B groupings with respect to
surface properties of the individual cells,
and enzymatic content and correlations
with clinical features have been noted.
The classification oflymphoproliferative
disorders has dramatically changed in the
last few years, as our understanding of
immunology has increased. Studies of
membrane properties and functional
attributes of the lymphocytes has led to a
better understanding of the biology of the
lymphomas. Subpopulations ofboth T and
B cells have been identified, and character-
istic lymphoma patterns can be related to
a homogeneous expansion of a particular
subpopulation. Inaddition, immunological
studies are providing information on the
sequence of cell-surface-related differ-
entiation in cells of the lymphocytic,
granulocytic and erythrocytic series.
The method of monoclonal antibody
production using mouse hybridomas
(Kohler & Milstein, 1975) is already prov-
ing of value, in addition to the more
generally available techniques for charac-
terizing cell-surface phenotypes within the
lymphoid malignancies. The biochemical
features of the antigenic determinants
reacting with monoclonal antibodies can
now be investigated, and this most im-
portant area of research is now open.
Monoclonal antibodies may be directed
against specific oligosaccharide sequences,
and can be used to dissect the chemistry
of the cell-surface glycoproteins. Pre-
liminary results suggest that the tech-
nique is of importance in determining the
immunological phenotype ofpatients with
diffuse large-cell lymphoma, and this may
be helpful in defining groups with different
survival prospects (Warnke et al., 1980).
Clearly, prospective studies involving
these new techniques in untreated patients
are likely to lead to a betterunderstanding
of the biology of these tumours, but the
prognostic weight ofeach parameter must
be measured against other known prog-
nostic features, using multi-variate
analysis. An approach has already been
made to evaluate enzyme and membrane
marker properties of leukaemia cells using
multi-parameter analysis (Janossy et al.,
1980).
The detection of cells of B lineage
belonging to a single clone in the periph-
eral blood ofpatients with lymphoma can
help confirm the diagnosis and define the
tumour type. Such studies also have rele-
vance in terms of staging (Garrett et at.,
1979; Ault et al., 1979). Abnormalities can
be detected in the presence of a normal
white cell count and differential using
anti-light-chain sera, but interpretation is
dependent on the ratio ofKappa: Lambda
bearing cells. Other techniques, such as
the detection of colchicine-sensitive
lymphoid cells in the peripheral blood
may also be helpful in this regard (Thom-
son et al., 1972; Scarffe et al., 1980).
These methods, however, are not the
only ones available for studying the com-
position ofthe plasma membrane in single
cells. A method of current interest to our
group in Manchester involves a study of
the biochemistry of the lymphoid cell sur-
face using plant-lectin binding assessed
by flow cytometry. A large number of
workers are contributing to the success of
these studies, but particular mention must
be made of Dr G. Blackledge who con-
ducted the flow-cytometric studies and
Dr J. Gallagher who provided the neces-
sary expertise in glycoprotein and lectin
chemistry. The immunological studies
were in collaboration with Dr B. Vose
(Department of Immunology, Paterson
Laboratories).
Lectins can be bound to fluorescein
isothiocyanate, and the amount attaching
to the plasma membrane ofsingle cells can
be determined by measuring the emission
of fluorescence from each cell in flow
cytometry. Differences in lectin binding
between cells within a separated popula-
tion may be investigated using this
method. Flow cytometry involves the
measurement of different properties of
cells passing singly at high speed through
a beam of light (Kamentsky et al., 1965).
Light scattering of the beam (related to
cell size) and emission of light from a
specific fluorescent probe can be assessed
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quantitatively for each cell. An interface
between the flow cytometer and a Desk
Top computer (HP9845S) allows a 3-
dimensional presentation of data for cell
size, number and fluorescence measure-
ments (Blackledge et al., 1980a). Cell
populations with different properties can
easily be recognizedI and selected for
further study, using this system. The
method is rapid and means that the lectin-
binding properties of several thousand
individual cells within a population can
be characterized.
The carbohydrate residues of glyco-
proteins and glycolipids are located on the
external face of the plasma membrane,
where they play an important part in cell
behaviour. The migratory properties of
normal lymphoid cells and their malignant
counterparts may well be determined to a
large extent by differences in cell-surface
chemistry. For these reasons, the study of
certain plant lectins with highly specific
saceharide-binding properties is being
undertaken. The technique with flowN
cytometry provides a tool for examining
the carbohydrate structure of the intact
plasma membrane of single cells.
Some lectins react only with certain
terminal sugar residues, others react with
sugars within the carbohydrate chaini, and
occasionally they may react specifically
with a particuilar sugar sequence. The use
of enzyvmes to remove terminal sugar
residtues, followed by further binding
studies with appropriate lectins, will allow
the concentration and/or affinity ofspecific
subterminal sugars to be determined.
When a lymphoid cell population is
obtained from peripheral blood by re-
moving the erythrocytes and phagocytic
cells, the lymphocytes show a character-
istic pattern of binding with 60% of the
cells having low binding to Lens calinatris
aggltitinin (LCA) and the remaining 40%0
showing considerably higher binding, in-
dependent of cell size. This plant lectin
binds to a-mannoside residues within the
carbohydrate chain, and binding can be
inhibited by the analogue a-methyl man-
noside. Separ-ation of the T lvmphocytes
31
on the basis ofthe capacity to form rosettes
with sheep red blood cells (E+) indicated
that most (80-870o) had low LCA binding,
whereas lymphocytes not binding to sheep
red blood cells (E-) had high binding
activity. The production of an enriched
T-cell population by removinig B cells in a
bead column coated with human Ig
reacted with human anti-Ig, produced a
similar binding pattern to the T-cell popu-
lation separated with sheep red cells.
Subsequent experiments uising a Beckton
Dickinson Fluorescence-activated Cell
Sorter 4, showed that E+ cells could be
separated on the basis of LCA binding
(Blackledge et al., in preparation). Study
of the patterns of inhibition with appro-
priate sugars indicate that the distinction
between T (E+) and non-T (E-) cells is
quantitative rather than qualitative, with
non-T cells having the greater number of
both high- and low-affinity sites for LCA.
This means that the concentration of N-
glycosidically-linked mannose containing
oligosaccharides is highest in the E- popul-
lation. Wheat germ agglutinin (WVGA)
binds to terminal sialic acid and N-acetyl
glucosamine residuies and can be used to
indicate the number of complete cell-
surface oligosaccharides. Experiments
with this lectin show increased binding in
the E- subset, indicating a higher sacehar-
ide chaiii density in these cells.
Fuirther experiments, in which stubsets
of lymphocytes wAithli different functional
characteristics were separated by a den-
sity-gradient technique, have allowed a
correlation to be made between functional
activity and lectin-binding properties
(Vose et al., in preparation). Studies in-
volving monoclonal antibodies and lectin
binding are providing the tools for separ-
ating subsets oflymplhocytes with different
functional capacity, <and provide a new
approach in removing unwanted immutne
cells from a marrow graft.
Cell-surface lectin-binding properties of
malignant lymphoid cells can be studied
by similar techniques. The lectin-binding
properties of acute leukaemia cells taken
from the peripheral blood differ markedly
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from those of a normal peripheral-blood
lymphocyte population, and cells of
myeloid and lymphoid lineage appear to
have distinctive features (Fig. 7). The
normal lymphocyte population is hetero-
geneous in lectin-binding properties,
whilst the leukaemia-cell population is
homogeneous. In the example shown in
Fig. 7, the ALL cells show low concan-
avalin A (Con A), LCA and WGA binding,
whereas the AML cells show much greater
binding to these lectins.
Studies of lymphoid cell populations in
the peripheral blood from patients with
lymphomas (Fig. 8) shows the marked
Fi-. 7. Lectin-bincding profiles of noimal
periplieral-bloo(l lymphocytes compare(d
wrvith acute-leukaemia cells. A (lolible peak
in Lenis culio(tris agglutiriin (LCA) binding
is seen in normal periplheral-bloodl lympho-
cytes, compare(l to a single peak in the more
homogeneouis sample of leukaemia cells.
Acute lymphoblastic leukaemia (ALL) cells
slhow low binding, wlhereas acute myelo-
blastic leukaemia (AM1L) cells showv high
binding of all 3 lectins. Peripheral-blood
lymploiod cells from the patient with Hodg-
kin's (disease (HD) show lheterogeneity, with
many of the cells showring very low Con-
canavalin A (Con A) binding, btit a small
population showing markedly increased
LCA andl Wheat Germ Agglutinin (W'GA).
heterogeneity of the blood lymphoid-cell
populations from lymphoma patients in
terms of lectin binding. The binding pat-
tern to Con A, LCA and WGA is quite
different from that of the normal lympho-
cyte population, and may indicate periph-
eral-blood involvement in the different
lymphomas. The binding properties can
return to normal after induction of re-
mission, and the study of binding profiles
could play a part in the continuing evalu-
ation of disease. Work is continuing in
characterizing clones of malignant cells
from patients with lymphoma in terms of
lectin binding and surface chemistry, and
we hope to relate this to their migratory
properties andthe behaviour ofthe tumour
in the patient.
FIG. 8. Lectin-binding profiles ofperipheral-
blood lymphoid cells from patients with
non-Hodgkin's lymphoma. These samples
from patients with diffuse histiocytic
lymplioma (DHL), diffiuse pooi-ly differenti-
ated lympliocytic (DPDL), nodular poorly
(lifferentiated lymphocytic (NPDL) ancd
nodular well differentiated lymphocytic
(NWDL) lympliomas slhow the lieterogen-
eity in lectin binding compared with the
normal lymphocytic population (Fig. 7);
several cell populations are visible.
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The abnormal lectin binding of lymph-
oid cells from the peripheral blood of
patients with Hodgkin's disease is of
interest (Fig. 7). Reactive lymphoid cells
are known to be increased in the periph-
eral blood of such patients, and it is
tempting to surmise that the markedly
increased LCA and WGA binding seen in
a proportion of the cells may be related to
this. The large number of cells with very
low Con A binding is also an interesting
feature, and requires further study.
A further technique involving the
assessment of lectin binding by fluores-
cence microscopy of lymph-node sections
has been devised, and this is providing
useful information on lectin binding to the
plasma and nuclear membrane of normal
lymphoid cells and malignant lymphoma
cells. In these studies the lymph-node
architecture remains intact and the work
is providing useful additional information
about differences between lymphomas
(Bramwell et al., unpublished observa-
tions).
I started my talk by illustrating the lack
of improvement in overall survival in
patients with NHL in England and Wales
during the 1960s and early 1970s. How-
ever, I hope I have demonstrated that
there is no need for pessimism. The im-
proved combined-modality treatment
already available for the least favourable
group of patients should now lead to some
improvement in these national figures.
The intensity of research into distinguish-
ing groups of patients with characteristic
malignant cells and biological behaviour
is leading to innovative approaches to
therapy likely to improve the welfare of
patients in the poor-risk groups. The paths
of basic research and clinical research are
closer in this subject than they have ever
been before, and it is clear that the 1980s
will be coloured by further exciting joint
ventures of value to the patient.
I -would like to thanbk my colleagues in the Alan-
chester Lymphoma Group for allowving me to publish
the data concerrning chemotherapy in the non-
Hodgkin's lymphoma of dliffuise pathology. Dr M1.
Palmer, Dr G. Blackledge, AMr R. Swindell and Dr V.
Blair were responisible for the development of the
computerized analysis presented here. I am most
grateful to my secretary, Airs B. Wthittle, for typing
the manuscript.
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